Effect of hydromorphone on ventilation in palliative care patients with dyspnea

Supportive Care in Cancer

Volumn 16, Issue 1, 2008, Pages 93-99

  Clemens, Katri Elina ^a,b   Klaschik, Eberhard ^a,b  

^a Malteser Hospital Bonn/Rhein Sieg   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer; Dyspnea; Hydromorphone; Opioids; Palliative medicine

Indexed keywords

HYDROMORPHONE;

ADULT; AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; BREATHING RATE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; LUNG VENTILATION; MALE; MONITOR; OXYGEN SATURATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE RATE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BLOOD GAS MONITORING, TRANSCUTANEOUS; CARBON DIOXIDE; DYSPNEA; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NEOPLASMS; OXYGEN; PALLIATIVE CARE; PROSPECTIVE STUDIES; PULSE; RESPIRATORY FUNCTION TESTS; RESPIRATORY MECHANICS; SEVERITY OF ILLNESS INDEX;

EID: 36949024899     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0310-3     Document Type: Article

References (28)

1. Abernethy AP, Currow DC, Frith P et al (2003). Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327:523-528
2. Babul N, Darke AC, Hagen N (1995) Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 10(3):184-186
3. Bennetton SA, Borges VM, Chang TKH, McErlane KM (2004) Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenoptica 34(4):3335-3344
4. Berkenbosch A, Olivier CN, Wosink JG, deGoede J, Ruprecht J (1994) Effect of morphine and physiostigmine on the ventilatory response to carbon dioxide. Anesthesiology 80:1303-1310
5. Berkenbosch A, Teppema LJ, Olivier CN, Dahanan A (1997) Influences of morphine on the ventilatory response to isocapnic hypoxia. Anesthesiology 86:1342-1349
6. Bourke DL, Warley A (1989) The steady state and breathing methods compared during morphine administration in humans. J Physiol 419:509-517
7. Bruera E, MacEachern T, Ripamonti C, Hanson J (1993) Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906-907
8. Bruera E, Macmillan K, Pither J et al (1990) Effects of morphine on the dyspnoea of terminal cancer patients. J Pain Symptom Manage 5:341-344
9. Bruera E, Sweeny C, Ripamonti C (2002) Management of dyspnea. In: Berger A, Portenoy R, Weissman D (eds) Principles and practice of palliative care and supportive oncology. Williams & Wilkins, Philadelphia, pp 357-371
10. Clemens KE, Klaschik E (2007) Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 33(4):473-481
11. Clemens KE, Klaschik E (2007). Respiratorische Symptome. In: Aulbert E, Nauck F, Radbruch L (eds) Lehrbuch der Palliativmedizin. 2. Auflage. Schattauer, Stuttgart, pp 375-393
12. Cone EJ, Darwin WD (1978) Simultaneous determination of hydromorphone, hydrocodone and their 6α and 6β hydroxyl metabolites in urine using selected ios recording with methane chemical ionization. Biomed Mass Spectrum 5:291-295
13. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RSJ, Corfield DR (2002) BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 88:1500-1511
14. Farncombe M, Chater S (1994) Clinical application of nebulised opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer 2:184-187
15. Farncombe M, Chater S, Gillin A (1994) The use of nebulised opioids for breathlessness: a chart review. Palliat Med 8:306-312
16. Gross JB, Blouin RT, Zandsberg S, Conrad PF, Häusler J (1996) Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanyl. Anesthesiology 85:713-720
17. Hagen NA, Foley KM, Cerbone DJ et al (1991) Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6(3):125-128
18. Heyse-Moore LH, Ross V, Mullee MA (1991) How much of a problem is dyspnoea in advanced cancer? Palliat Med 5:20-26
19. Klaschik E (2006) Dyspnoe. In: Husebø S, Klaschik E (eds) Palliativmedizin. Aktualisierte, 4. Auflage. Springer, Berlin, Heidelberg, New York, pp 276-279
20. Lawlor P, Turner K, Hanson J, Bruera E (1997) Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72:79-85
21. Mazzocato C, Buclin T, Rapin C (1999) The effects of morphine on dyspnoea and ventilatory function in elderly patients with advanced cancer: a randomized double blind controlled trial. Ann Oncol 10:1511-1514
22. Moriarty M, McDonald CJ, Miller A (1999). A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Clin Res 2:1-8
23. Quigley C (2002) Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev (1):CD003447
24. Santiago TV, Johnson J, Riley DJ Edelman NH (1979) Effects of morphine on ventilatory response to exercise. J Appl Physiol 47:112-118
25. Sarhill N, Walsh D, Khawam E, Tropiano P, Stahley MK (2000) Nebulized hydromorphone for dyspnoea in hospice care of advanced cancer. Am J Hosp Palliat Care 17(6):389-391
26. Weil JV, McCullough RE, Kline JS, Sodal I (1975) Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal men. N Engl J Med 292:1103-1106
27. Wilson RH, Hoshet W, Dempsey ME (1954) Respiratory acidosis: effects of decreasing respiratory minute volume in patients with chronic pulmonary emphysema, with specific reference to oxygen, morphine and barbiturates. Am J Med 18:464-470
28. Zebraski SE, Kochenash SM, Raffa RB (2000) Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 66:2221-2231